Biodexa Pharmaceuticals (BDRX) EBT (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted EBT of -$5.3 million for Q2 2025, down 20.23% sequentially from -$4.4 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) EBT (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported EBT for 12 years, with the latest figure at -$5.3 million in Q2 2025.
- Quarterly EBT changed N/A year-over-year to -$5.3 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$23.8 million (changed N/A YoY) and the FY2025 annual result came in at -$8.6 million, down 11.49% from the prior year.
- EBT fell to -$5.3 million in Q2 2025 per BDRX's latest filing, from -$4.4 million in the prior quarter.
- Over five years, EBT peaked at -$4.2 million in Q3 2022 and troughed at -$10.0 million in Q4 2022.
- A 5-year average of -$6.4 million and a median of -$5.1 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2021 and 2022: EBT soared 79.06% in 2021, then fell 20.96% in 2022.
- Over 5 years, EBT stood at -$8.2 million in 2021, then retreated by 20.96% to -$10.0 million in 2022, then grew by 6.69% to -$9.3 million in 2023, then soared by 52.57% to -$4.4 million in 2024, then dropped by 20.23% to -$5.3 million in 2025.
- According to Business Quant data, EBT over the past three periods registered -$5.3 million, -$4.4 million, and -$9.3 million for Q2 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -5.30 Mn |
| Dec 31, 2024 | -4.41 Mn |
| Dec 31, 2023 | -9.29 Mn |
| Jun 30, 2023 | -4.83 Mn |
| Dec 31, 2022 | -9.96 Mn |
| Sep 14, 2022 | -4.20 Mn |
| Dec 31, 2021 | -8.23 Mn |
| Sep 17, 2021 | -4.71 Mn |
| Dec 31, 2020 | -30.99 Mn |
| Sep 10, 2020 | -22.49 Mn |
| Dec 31, 2019 | -14.04 Mn |
| Dec 31, 2018 | -15.96 Mn |
| Dec 31, 2016 | -13.96 Mn |
| Dec 31, 2015 | -44.50 Mn |
| Dec 31, 2014 | -15.59 Mn |
| Dec 31, 2013 | -7.91 Mn |